It is made available under a CC-BY-NC-ND 4.0 International license .

1	
2	
3	Gut microbiome dysbiosis and immune activation correlate with somatic and
4	neuropsychiatric symptoms in COVID-19 patients
5	
6	
7 8	Microbiome dysbiosis linked to COVID-19 symptoms.
9 10 11 12 13	Paula L. Scalzo ^{1,2,3} [†] , Austin Marshall ^{1,2,4} [†] , Sirena Soriano ^{1,2} , Kristen Curry ^{4,5} , Mario Dulay ¹ , Timea Hodics ¹ , Eamonn MM Quigley ⁶ , Todd J. Treangen ^{4,7} , María M. Piskorz ⁸ , Sonia Villapol ^{1,2,9,*}
.4	
.5	¹ Department of Neurosurgery, Houston Methodist Research Institute, Houston, TX, USA
.6	² Center for Neuroregeneration, Houston Methodist Research Institute, Houston, TX, USA
.7 .8	³ Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, MG, Brazil
.9	⁴ Department of Computer Science, Rice University, Houston, TX, USA
20 21	⁵ Department of Computational Biology, Institut Pasteur, Université Paris Cité, Paris 75015, France
22 23	⁶ Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.
24	⁷ Department of Bioengineering, Rice University, Houston, TX, USA
25 26	⁸ Department of Neurogastroenterology, Hospital de Clinicas José de San Martin, Universidad de Buenos Aires, Argentina.
27 28 29	⁹ Department of Neuroscience in Neurological Surgery, Weill Cornell Medical College, NY, USA
30 31	†These authors contributed equally to this work.
32 33 34 35 36 37 38 39 40 41	*Corresponding author: Sonia Villapol, Ph.D. Center for Neuroregeneration and Department of Neurosurgery, Houston Methodist Research Institute, 6670 Bertner Avenue, R11-212, Houston, TX 77030, USA. <i>Email: svillapol@houstonmethodist.org</i> . ORCID_0000-0002-6174-4113
⊮∠ 3	

It is made available under a CC-BY-NC-ND 4.0 International license .

15 Abstract

COVID-19 patients often exhibit altered immune responses and neuropsychiatric symptoms during hospitalization. However, the potential interactions with gut microbiome profiles have not been fully characterized. Here, COVID-19 disease severity was classified as low (27.4%), moderate (29.8%), and critical (42.8%). Fever (66.1%) and cough (55.6%) were common symptoms. Additionally, 27.3% reported somatic symptoms, 27.3% experienced anxiety, 39% had depressive symptoms, and 80.5% reported stress. Gut microbiome profiling was performed using full-length 16S rRNA gene sequencing. Elevated interleukin-6 levels were observed in the most severe cases, indicating systemic inflammation. Reduced gut bacterial diversity was more pronounced in women and obese patients and correlated with higher disease severity. The presence of the genus Mitsuokella was significantly associated with increased physical, stress, anxiety, and depressive symptoms, and Granulicatella with critically ill patients. These findings suggest a link between mental health status, systemic inflammation, and gut dysbiosis in COVID-19 patients, emphasizing the potential of microbiome-targeted therapies to improve recovery and reduce severe complications.

)3

It is made available under a CC-BY-NC-ND 4.0 International license .

³⁴ Introduction

)5 Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome)6 coronavirus 2 (SARS-CoV-2), primarily presents with respiratory symptoms. However, the)7 infection can also affect neurological(1) and gastrointestinal (GI) systems(2, 3). It is well)8)9 established that men are at a higher risk than women of developing severe acute COVID-19(4, 5), as well as individuals over the age of 60 years old(6, 7). Patients hospitalized)0 during the acute phase of COVID-19 exhibit a high prevalence of mental health issues such)1 as elevated stress, anxiety, and depression (8-10). These mental health disturbances are more)2 prevalent in women and can be worsened by factors such as age(11), more severe physical)3 symptoms, or length of hospital stay(12). Furthermore, the presence of COVID-19)4 symptoms at the time of admission adds to the psychological burden(13).)5

- SARS-CoV-2 infection increases levels of soluble immune mediators in the bloodstream, such as inflammation-related cytokines(14). It activates intestinal angiotensin-converting enzyme 2 (ACE2) receptors(15) and damages the intestinal epithelium, disrupting the gut barrier(16, 17), as observed in patients with severe COVID-19(18, 19). This inflammatory response triggers GI and alterations in the gut microbiome(19-21), both of which are associated with disease severity.
- Gut dysbiosis, characterized by a reduction in butyrate-producing, anti-inflammatory 2 bacteria, and increased pro-inflammatory taxa, disrupts immune regulation, nutrient 3 metabolism, and structural defenses, contributes to systemic inflammation and impairs host 4 homeostasis(22). Microbiome imbalances during the acute phase of COVID-19, especially 5 in hospitalized patients, were linked to increased mortality rates(23). Previous studies have 6 identified microbial features in the gut and airways of COVID-19 patients during 17 hospitalization and recovery(21), suggesting that microbial markers could serve as 8 noninvasive diagnostic tools. Microbiome dysbiosis also affects immune and inflammatory 9 response regulation and brain function(24). However, the link between microbial alterations 20 and somatic or neuropsychiatric symptoms in COVID-19 patients and their potential as 21 predictive tools has yet to be fully elucidated. 22
- In this cross-sectional study, we identified associations between somatic and neuropsychiatric symptoms, inflammatory profiles, and alterations in gut microbiota composition in hospitalized COVID-19 patients. By examining these relationships, we aim to gain insights into the mechanisms underlying COVID-19 pathogenesis and potentially identify novel therapeutic targets for intervention.
- 28
- **Results**
- 30 31

Characteristics of the participants.

We enrolled 124 COVID-19 patients, 63 males and 61 females. The mean age was 55.2 (±14.6) years. The average length of hospital stay was 7 days (range, 1 to 21 days), and a total of 8 (6.5%) patients died during their initial hospital stay. According to the COVID-19 Severity Index, 34 (27.4%) patients were classified as low, 37 (29.8%) as moderate, and 53 (42.8%) as critical COVID-19. Older patients experienced more severe COVID-19 symptoms (p < 0.001), and the prevalence of men increased with the severity of the disease (p = 0.025). Data are summarized in **Table 1**.

It is made available under a CC-BY-NC-ND 4.0 International license .

19 Table 1. Demographic and clinical characteristics of the patients classified according to the

COVID-19 Severity Index (n=124).

40 41

Variables	All patients		COVID-19		
	(n=124)		Severity		
		Low	Moderate	Critical	p Value
		(n=34)	(n=37)	(n=53)	
Age, years, mean \pm SD	55.2 ± 14.6	42.3 ± 11.1	55.5 ± 12.8	63.2 ± 11.6	< 0.001#
<60 years, n (%)	78 (62.9)	34 (100)	24 (64.9)	20 (37.7)	
≥60 years, n (%)	46 (37.1)	0	13 (35.1)	33 (62.3)	
Gender, n (%)					0.025\$
Male	63 (50.8)	12 (35.3)	17 (45.9)	34 (64.2)	
Female	61 (49.2)	22 (64.7)	20 (54.1)	19 (35.8)	
Body Mass Index (BMI),	30.7 ± 6.6	28.7 ± 4.7	30.5 ± 6.2	32.2 ± 7.5	0.050#
kg/m ² , mean \pm SD					
$<30 \ kg/m^{2}$	67 (54.0)	24 (70.6)	20 (54.1)	23 (43.4)	
$\geq 30 \text{ kg/m}^2$	57 (46.0)	10 (29.4)	17 (45.9)	30 (56.6)	
Co-morbidities, n (%)					
Diabetes mellitus	4 (3.2)	0	2 (5.4)	2 (3.8)	0.570*
Heart diseases	5 (4.0)	0	0	5 (9.4)	0.044*
Hypertension	38 (30.6)	5 (14.7)	12 (32.4)	21 (39.6)	0.047\$
Chronic pulmonary	8 (6.5)	0	1 (2.7)	7 (13.2)	0.032*
obstructive disease					
Days of hospitalization,	7 (4 – 9)	7 (4 – 8)	6 (4 – 8.5)	7 (4 – 10.5)	0.455 ^{&}
median (IQR)					
Intensive <i>care</i> unit (ICU)	13 (10.5)	0	2 (5.4)	11 (20.8)	< 0.001*
Supplemental oxygen, n	58 (46.8)	0	8 (21.6)	50 (94.3)	< 0.001\$
(%)					
Antibiotics, n (%)	25 (20.2)	3 (8.8)	9 (24.3)	13 (24.5)	0.154\$
Death during	8 (6.5)	0	1 (2.7)	7 (13.2)	0.032*
hospitalization, n (%)					
Number of COVID-19	3 (2-4)	3 (2-4)	3 (2 – 3)	3 (2-4)	0.287&
symptoms					

12 13

Note: Data were presented using absolute values and percentages (%), mean and standard deviation (SD) or median and interquartile range (IQR). ^{\$}Chi square test. *Fisher's exact test (FET). [#]One-way ANOVA. [&]Kruskal-Wallis test.

14 15

COVID-19 symptoms, somatic and neuropsychiatric assessments, and inflammatory profile.

Patients (n=43, 34.7%) experienced at least 3 of the 16 assessed COVID-19 symptoms at baseline. Fever (n=82, 66.1%) and cough (n=69, 55.6%) were the most common symptoms. A significant association was found between COVID-19 severity and the presence of

il dyspnea (p<0.001). The distribution of symptoms at the time of hospital admission,

categorized by COVID-19 severity, is represented in Fig. 1a. Among the 77 patients who 52 53 completed the instruments, 21 (27.3%) were classified as having severe somatic symptoms 54 as intense and persistent pain, chronic fatigue, headaches, muscle, and joint pain or sleep disturbances. In terms of neuropsychiatric symptoms, 21 (27.3%) exhibited symptoms of 55 anxiety, and 30 (39%) reported depressive symptoms. Regarding perceived stress, 15 56 patients (19.5%) reported rarely or never feeling stressed, 36 patients (46.7%) experienced 57 stress occasionally, and 26 patients (33.8%) reported often or usually feeling stressed. 58 59 Scores for PHQ-15 (Fig. 1b), PSS (Fig. 1c), HADS-A (Fig. 1d), and HADS-D (Fig. 1e) showed no significant differences across COVID-19 Severity Index groups, nor did they 50 vary significantly with age or BMI (Table 2). Additionally, there were no significant 51 differences in the prevalence of somatic, stress, or depressive symptoms between male and 52 female patients. However, anxiety symptoms were more prevalent among women, who also 53 scored higher on the HADS-A (Table 2). The prevalence of fever was higher among those 54 with severe (PHQ ≥ 15) somatic symptoms ($\chi^2(1)=4.586$; p=0.032). There were significant 55 correlations between PHQ-15 and PSS (Fig. 1f), HADS-A (Fig. 1g), and HADS-D (Fig. 56 **1h**). An association was found between stress, anxiety, and depressive symptoms scores. 57 Higher stress levels were correlated with more extended hospital stays ($r_s=0.227$; p=0.047). 58

The levels of the inflammatory mediators - interleukin (IL) (IL-6, IL-12, IL-10), IL-1 59 receptor antagonist (IL-1ra), interferon-gamma (IFN-y), and interferon-gamma-inducible 70 71 protein 10 (IP-10) were higher with increased severity of SARS-CoV-2 infection (Fig. 1i**n**). On the other hand, platelet-derived growth factor BB (PDGF-BB), regulated on 12 activation, normal T cell expressed and secreted (RANTES), and interleukin-2 (IL-2) were 13 lower in critically ill patients (Fig. 10-q). There were no differences in the other measured 14 inflammatory mediators (Supplementary Fig. 1). The scores obtained in the PHQ-15 were 15 associated with interleukin-7 (IL-7), interleukin-13 (IL-13), eotaxin, and PDGF-BB levels. 16 PSS and IL-13 were correlated. Anxiety scores were correlated with IL-12. The scores 17 obtained in the HADS-D were associated with IL-1ra and IL-2. The heatmap displays the 78 statistically significant correlations (Fig. 1r). 79

Additionally, the number of neutrophils in circulation increased in moderate and critical patients compared to those with low COVID-19 severity, whereas circulating lymphocytes decreased. An increase in the NLR and PLR accompanied these changes. CRP, D-dimer, fibrinogen, ferritin, and LDH were elevated with COVID-19 severity. Albumin concentration decreased in moderately severe and critically ill patients (**Supplementary Fig. 2**).

36





38 39

37

)0

)]

Fig. 1. COVID-19 symptom prevalence, somatic and neuropsychiatric assessments in hhospitalized COVID-19 patients. (a) The prevalence of COVID-19 symptoms during hospitalization is categorized into low, moderate, and critical severity groups. The most common symptoms were fever (66%), cough (56%), and dyspnea (29%) which was more

It is made available under a CC-BY-NC-ND 4.0 International license .

prevalent in the critical group (p < 0.001). The chi-square or Fisher's exact test was used to)2 analyze contingency tables. Median and interquartile range of the clinical outcomes results)3 of the patients classified according to the COVID-19 Severity Index (n=77). (b) Somatic)4 symptoms (PHQ-15, Patient Health Questionnaire-15), (c) perception of stress (PSS,)5 Perceived Stress Scale). (d) anxiety, and (e) depression (HADS-D, Hospital Anxiety and)6 Depression Scale) scores were the same across the three groups categorized by COVID-19)7 severity (low, moderate, and critical). Pairwise comparisons between severity groups)8)9 followed the Kruskal-Wallis test. Spearman's Rank Correlation Coefficient showed a positive correlation between PHQ-15 scores and (f) PSS scores ($r_s=0.347$, p=0.002), (g))0 HADS-A scores ($r_s=0.475$, p<0.001) and (h) HADS-D scores ($r_s=0.252$, p=0.027). These)1 results indicate that higher somatic symptom burden is associated with increased perceived)2 stress, anxiety, and depressive symptoms in hospitalized COVID-19 patients. The)3 concentrations (pg/ml) of (i) IL-6, (j) IL-12, and (k) IL-1ra were higher in the critical group)4 compared to the low group. For (1) IFN- γ and (m) IL-10, the critical group showed higher)5 levels compared to the low and moderate groups. The levels of (n) IP-10 were higher in the)6 critical and moderate groups compared to the low group. Conversely, the levels of (0))7 PDGF-BB, and (p) RANTES decreased from the low group to the critical group. For (q))8 IL-2, the critical group showed lower levels than the low and moderate groups. Pairwise)9 comparisons between the severity groups followed the Kruskal-Wallis test. The lines and p-0 values on the Fig.s indicate significant differences between these groups. Linear regression 1 2 was used to compare variables with and without adjustment for age, gender, and BMI. Age influenced IFN-y serum concentration. Both age and BMI affected the differences in IL-12 3 and RANTES levels. For the rest of the cytokines (IL-1ra, IL-2, IL-6, IL-10, IP-10, PDGF-4 BB), the factor responsible for the differences in concentrations was the severity of COVID-5 19. (r) Heatmap illustrating the correlations between various cytokine levels in serum 6 concentration (% coefficient of variation) and somatic and neuropsychiatric symptoms 17 scores in hospitalized COVID-19 patients, with significant correlations marked with 8 asterisks (*p<0.05, **p<0.01, ***p<0.001). Red shades represent positive correlations, 9 whereas blue shades represent negative correlations. The Kruskal-Wallis test was followed 20 21 by pairwise comparisons between severity groups with correction for multiple testing. IL, Interleukin; IL-1ra, Interleukin-1 receptor antagonist; IFN-y, Interferon-gamma; IP-10, 22 Interferon-gamma-inducible protein 10; PDGF-BB, Platelet-Derived Growth Factor BB; 23 RANTES, Regulated on Activation, Normal T Cell Expressed and Secreted. 24

It is made available under a CC-BY-NC-ND 4.0 International license .

			• 1			` '		
Variables	PHQ-15		PSS		HADS-A		HADS-D	
	Median	р	Median	р	Median	р	Median	р
	(IQR)	Value	(IQR)	Value	(IQR)	Value	(IQR)	Value
Gender								
Female	10 (7 –	0.393	23 (14 –	0.332	6 (3.5 –	0.014	7 (3 –	0.216
	14.5)		31.5)		13)		10.25)	
Male	8 (6.25 –		19 (15 –		4 (2 –		5 (1.25 –	
	15)		27.5)		6.75)		9.75)	
Age								
<60 years	9.5 (5.75	0.369	20.5 (14 –	0.398	5 (3 – 8)	0.487	6 (3 –	0.751
	- 15)		28.25)				10)	
≥ 60 years	8 (8 –		22 (16 –		6 (3 –		5 (2 –	
	16)		31)		14)		12)	
BMI								
$< 30 \text{ kg/m}^2$	8 (5 –	0.222	22 (14 –	0.919	5 (3 – 7)	0.536	6 (3 –	0.707
	14)		28)				10)	
$\geq 30 \text{ kg/m}^2$	10 (7.75		19.5 (16 –		6 (3 – 9)		5.5 (2 –	
	- 16)		29.25)				10)	
COVID-19								
severity								
Low	9.5 (5 –	0.864	27 (14.5 –	0.172	5 (3 –	0.496	7 (3 –	0.431
	14.25)		31.25)		8.25)		10)	
Moderate	9.5 (7 –		18.5 (14 –		5.5 (3 –		6 (2.5 –	
	13.75)		26.75)		13)		10.5)	
Critical	8 (7 –		19 (15 –		5 (2 – 7)		4 (1 – 8)	
	16)		26)					

Table 2. Somatic and	l neuropsychiat	ric symptoms of the	e participants	(n=77).
----------------------	-----------------	---------------------	----------------	---------

Note: Comparison of scores on instruments assessing somatic symptoms, stress, anxiety, and depressive symptoms according to gender, age, BMI, and COVID-19 severity. Abbreviations: BMI, Body Mass Index; HADS-A, *Hospital Anxiety and Depression Scale-Anxiety;* HADS-D, *Hospital Anxiety and Depression Scale-Depression;* IQR, interquartile range; *PHQ-15, Patient Health Questionnaire-15; PSS, Perception of stress. Mann-Whitney U test or* Kruskal-Wallis test was followed by pairwise comparisons between groups.

27

28

29

25

Impact of COVID-19 severity on gut microbiome composition: associations with BMI, gender, and age.

The analysis of alpha diversity (Shannon index) (**Fig. 2a**) revealed a significant reduction in gut microbiota diversity in critically ill COVID-19 patients compared to those with low disease severity (p<0.05). Regarding species richness (Chao1 index) (**Fig. 2b**), critically ill patients showed significantly lower richness compared to those with low (p<0.01) and moderate (p<0.05) disease severity. Beta diversity analyses (MDS plots) demonstrated that BMI significantly correlated the gut microbiota composition in patients classified as having low COVID-19 severity (**Fig. 2c-e**), with a distinct separation between patients with BMI

It is made available under a CC-BY-NC-ND 4.0 International license .

37 18	\geq 30 and those with BMI under 30. Gender-based analysis (Fig. 2f-h) significantly correlated microbioto composition only in oritically ill national (Fig. 2h). Similarly, and was
8	microbiota composition only in critically in patients (Fig. 21). Similarly, age was
39	significantly associated with microbiota composition in the critically ill group, with patients
10	\geq 60 years showing distinct microbial profiles compared to those under 60 years (Fig. 2k).
1	Bar plots of microbial relative abundance at the family (Fig. 2l) and genus levels (Fig. 2m)
12	demonstrated considerable shifts in microbial composition across severity groups.

It is made available under a CC-BY-NC-ND 4.0 International license .



It is made available under a CC-BY-NC-ND 4.0 International license .

Fig. 2. Alpha and beta diversity of gut microbiome in hospitalized COVID-19 patients.

15 (a) Shannon index, which measures species richness and evenness, indicating lower diversity in the critical group compared to the low group (p=0.0129) (b) Chao1 richness 16 estimator indicates significantly lower species counts in the critical group compared to the 17 low group (p=0.0073) and the moderate group (p=0.0197) (*p<0.05 and **p<0.01). (c-e) 18 Beta diversity analysis was performed using Aitchison Principal Coordinates Analysis 19 (PCoA) for Body-mass-index (BMI) categories (<30 vs. ≥ 30 kg/m²), showing distinct 50 51 clustering in the low group (p=0.034). (f-h) PCoA plots for gender (female vs. male) show distinct clustering in the critical severity group (p=0.009), suggesting gender-based 52 differences in microbiome composition are more pronounced in this group. (i-k) PCoA plots 53 for age categories (<60 vs. ≥ 60 years) show a more distinct clustering in the critical group 54 (p=0.006), indicating age-related differences in microbiome composition. The statistical 55 significance of these groupings was assessed using permutational multivariate analysis of 56 variance (Permanova) within the vegan R package, with Pr(>F) and R² values confirming 57 the observed differences in microbial community composition. The relative abundance of 58 various gut microbiota showing the top 15 taxa at family level (I) and genus level (m) in 59 hospitalized COVID-19 patients across different severity groups. 50

51 **Differential gut microbial signatures across COVID-19 severity.**

14

Analysis of the Composition of Microbiomes with Bias Correction 2 (ANCOMBC2) can 52 potentially uncover biomarkers or therapeutic targets by providing a list of bacteria with 53 significant changes in abundances. The heatmap (Fig. 3a) shows the centered log-ratio 54 abundance of gut microbial species across patients with low, moderate, and critical COVID-55 19 severity. A clear shift in microbial composition was observed as disease severity 56 increased, with certain species becoming more abundant in critically ill patients while others 57 decreased. The graphs within Fig. 3b and Fig. 3c show log fold changes of specific bacterial 58 species between low to moderate and low to critical severity groups, respectively. Notably, 59 species such as Streptococcus periodonticum and Clostridium perfringens were 70 significantly enriched in patients with lower disease severity (q<0.001 and q<0.01) (Fig. 3b 71 and Fig. 3c). In comparison, Klebsiella pneumonia and Prevotella loescheii were highly 12 abundant in critically ill patients (q<0.001 and q<0.01) (Fig. 3c). 13

It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 3. Heatmap and differential abundance of specific gut microbiota taxa in hospitalized COVID-19 patients across different severity groups. (a) Heatmap of the centered-log transformed abundance of significantly altered taxa showing intra-group variation among patients with the same COVID-19 severity, highlighting distinct microbial

profiles associated with each group. The color intensity represents the transformed 79 30 abundance, with darker shades of red indicating higher abundance. (b) Comparison between low and moderate-severity groups reveals significant increases in taxa such as 31 Desulfonispora thiosulfatigenes and Streptococcus vestibularis in moderate group. It 32 decreases in taxa such as Streptococcus periodonticum, Phocaeicola plebius, and 33 Clostridium perfringens in moderate group. (c) Comparison between low and critical 34 severity groups shows significant increases in taxa such as *Klebsiella pneumoniae*, 35 Prevotella loeschii, and Breznakia pachnodae with corresponding decreases in 36 Ruminiclostridium cellulolyticum, Streptococcus periodonticum, and 37 Suterella wadsworthensis in critical group; identified using ANCOMBC2. The analysis revealed 38 differentially abundant species with statistical significance levels indicated as *q<0.05, 39 **q<0.01, and ***q<0.001.)0

Association of gut microbiota with somatic symptoms, stress, anxiety, and depressive symptoms in COVID-19 patients.

Principal Coordinates Analysis (PCoA) was performed to investigate associations between)3 somatic and neuropsychiatric symptoms and gut microbiome composition in patients with)4 COVID-19 (Fig. 4a-I). A statistically significant association was found between)5 somatization, as measured by the PHQ-15, and microbiome composition within the)6 moderate severity group (p=0.04, R²=0.029; Fig. 4b). This finding suggests that individuals)7 with higher somatic symptom scores may exhibit distinct microbial profiles compared to)8 those with lower scores. Similarly, perceived stress showed a non-significant trend with the)9 microbiome in the moderate group (p=0.05, R²=0.084; Fig. 4e), indicating that experiencing)0 stress regularly could influence microbial community composition. The relatively higher R²)1 value for PSS suggested that perceived stress explained a notable portion of the observed)2 variance in microbial composition compared to other mental health factors. In contrast,)3 scores from the HADS-A and HADS-D tests did not display significant associations with)4 microbiome composition across all severity groups (p>0.05; Figs. 4g-5l). These results)5 suggest that, in this sample, general measures of anxiety and depressive symptoms may not)6 significantly contribute to variations in gut microbial structure.)7

It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 4. Ordination analyses of gut microbiota composition, somatic and neuropsychiatric symptoms across COVID-19 severity levels. (a-c) Aitchison distance principal coordinate analysis plots explore the relationships between COVID-19 severity, gut microbiota composition, somatic symptoms (PHQ-15) (d-f), and neuropsychiatric symptoms, including stress (PSS) (a-l), anxiety (HADS-A) (g-i), depressive symptoms (HADS-D) (j-l). The distributions indicate varying degrees of correlation between gut microbiota diversity and mental health indicators, with Permanova (>F) and R² values specified for each plot.

)8

)9

0

1

2

3

4

5

.6

.7

8

19 20

21

22 23

24

25

A secondary differential abundance analysis revealed microbial shifts correlated with scores on the PHQ-15, PSS, HADS-A, and HADS-D assessments. Patients with higher PHQ-15 scores showed a significant increase in the abundance of species such as *Enterococcus citroniae* (q<0.001), *Phascolarctobacterium succinatutens and Acidaminococcus intestine* (q<0.01), and *Enterococcus faecalis* (q<0.05), while known beneficial bacteria like *Lactobacillus rugosae* were significantly depleted (q<0.05) (**Fig. 5a**). Higher PSS scores were associated with an overrepresentation of *Enterocloster asparagiformis* (q<0.001), and *Blautia stercoris* (q<0.05). At the same time, species *Blautia hansenii*, *Salmonella enterica*, and *Prevotella stercorea* (q<0.05) were significantly decreased (**Fig. 5b**). HADS-A scores

It is made available under a CC-BY-NC-ND 4.0 International license .

were linked to an increase in *Dialister succinatiphilus* (q < 0.05) and *Streptococcus sp. A12* (q < 0.01), among others, showed a notable reduction in species such as *Lactobacillus salivarius* (q < 0.001) and *Bacteroides caccae* (q < 0.01) (**Fig. 5c**). Higher HADS-D were correlated with elevated levels of *Butyricimonas virosa* (q < 0.05), and *Eubacterium* xylanophilum (q < 0.01). In contrast, species *Bacteroides caccae* (q < 0.01) and *Ruminiclostridium cellulolyticum* (q < 0.05) were significantly diminished (**Fig. 5d**).

It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 5. Differential abundance analysis between gut microbiota, somatic and neuropsychiatric symptoms in hospitalized COVID-19 patients. Log fold changes in abundance of various bacterial taxa associated with four different assessments: (a) PHQ-15 (somatic symptoms), (b) PSS (perceived stress), (c) HADS-A (anxiety), and (d) HADS-D

It is made available under a CC-BY-NC-ND 4.0 International license .

(depressive symptoms). The analysis used ANCOMBC2 to identify differentially abundant microbes between high- and low-test scores. Bars represent log fold changes in microbial abundance, with red bars indicating an increase and blue bars indicating a decrease in abundance associated with higher test scores. Error bars represent standard errors calculated using ANCOMBC2. Asterisks (*q<0.05, **q<0.01, and ***q<0.001) denote statistical significance levels, with more asterisks indicating higher significance. Only the top differentially abundant taxa are shown for each scale (LFC \geq 1).

Distinct gut microbial correlations with somatic symptoms, stress, anxiety, and depressive symptoms in COVID-19 patients.

The heatmap presents the Spearman correlation coefficients of CLR-transformed 16 abundances between various bacterial species and four assessments: PHQ-15, PSS, HADS-17 A, and HADS-D (Fig. 6). Several microbial species showed significant correlations with 18 these symptoms, with only associations where p<0.05 displayed numerically to highlight 19 statistically significant relationships. For instance, *Christensenella minuta* (p<0.01), 50 Anaeromassilibacillus senegalensis. Lachnospiraceae bacterium GAM79. and 51 Christensenella massiliensis (p<0.05) were negatively associated with somatic symptoms 52 (PHQ-15), showing a significant reduction. Conversely, Mitsuokella jalaludinii, Prevotella 53 copri, and Phocaeicola plebeius were positively associated with increased PHQ-15 scores 54 (p<0.05). Notably, *Mitsuokella jalaludinii* showed significant positive correlations with all 55 assessments (p < 0.05), indicating a potential association between its increased abundance 56 and higher symptom burden. Additionally, Phocaeicola vulgatus correlates with PSS and 57 HADS-D (p<0.05). Bacteroides stercoris correlates with HADS-D (p<0.05). 58

It is made available under a CC-BY-NC-ND 4.0 Inter
--

Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusStreptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcusBacteroides thetaiotaomicronImage: streptococcusImage: streptococcusFaecalibacterium prausnitziiImage: streptococcusImage: streptococcusFaecalibacterium prausnitziiImage: streptococcusImage: streptococcusFaecalibacterium prausnitziiImage: streptococcusImage: streptococcusClostridium saccharogumiaImage: streptococcusImage: streptococcusBacteroidales bacterium CFImage: streptococcusImage: streptococcusSuccinivibrio dextrinosolvensImage: streptococcusImage: streptococcusRuminococcus gnavusImage: streptococcusImage: streptococcusStreptococcus thermophilusImage: streptococcusImage: streptococcusStreptococcus thermophilusImage: streptococcusImage: streptococcusBacteroides faecisImage: streptococcusImage: streptococcusChristensenella massillensis0.0057Image: streptococcusChristensenella massillensis0.00242Image: streptococcusPhocaeicola vulgatusImage: streptococcusImage: streptococcusChristensenella massillensis0.00242Image: streptococcusPrevotella copriImage: streptococcusImage: streptococcusBacteroides streptorisImage: streptococcusImage: streptococcus </th <th></th> <th>PHQ-15</th> <th>PSS</th> <th>HADS-A</th> <th>HADS-D</th> <th></th>		PHQ-15	PSS	HADS-A	HADS-D	
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusImage: streptococcus sali	Phocaeicola plebeius	0.0402				
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusImage: streptococcus salivariusStreptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusImage: streptococcusEubacterium prausnitziiImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumPhascolarctobacterium faeciumImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumClostridium saccharogumiaImage: streptococcus gnavusImage: streptococcus streptococcus torquesImage: streptococcus streptococcus thermophilusRuminococcus gnavusImage: streptococcus thermophilusImage: streptococcus streptococcus thermophilusImage: streptococcus streptococcus thermophilusStreptococcus thermophilusImage: streptococcus streptococcus thermophilusImage: streptococcus streptococcus streptococcus thermophilusImage: streptococcus streptococus streptococcus streptococus streptococcus streptococus s	Lactococcus piscium					
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusImage: streptoccus salivariusImage: streptoccus salivariusImage: streptoccus salivariusImage: streptoccus salivariusImage: streptocus salivariusImage: streptocus salivariusImage: streptocus salivariusIm	Leuconostoc gelidum					
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusImage: streptococcus streptococcus streptococcus streptosImage: streptococcus streptosStreptococcus strempsilus0.0057Image: streptosImage: streptosImage: streptosImage: streptosImage: streptosAnaeromassilibacillus senegalensis0.0150Image: streptosImage: streptosImage: streptosImage: streptos <tr< td=""><td>Eubacterium rectale</td><td></td><td></td><td></td><td></td><td></td></tr<>	Eubacterium rectale					
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusImage: streptococcus streptococcus faeciumImage: streptocus faeciumImage: stre	Prevotella copri	0.0242				
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusStreptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusEubacterium siraeumImage: streptococcus faeciumImage: streptococcus faeciumFaecalibacterium prausnitziiImage: streptococcus faeciumImage: streptococcus faeciumPhascolarctobacterium faeciumImage: streptococcus faeciumImage: streptococcus faeciumPhascolarctobacterium faeciumImage: streptococcus faeciumImage: streptococcus faeciumRuminococcus gnavusImage: streptococcus thermophilusImage: streptococcus thermophilusBacteroides faecisImage: streptococcus thermophilusImage: streptococcus thermophilusBacteroides faecisImage: streptococcus thermophilusImage: streptococcus thermophilusChristensenella minuta0.0057Image: streptococcus thermophilusLachnospiraceae bacterium GAM790.0485Image: streptococcus thermophilusLachnospiraceae bacterium GAM79Image: streptococcus thermophilusPhocaeicola vulgatusImage: streptococcus thermophilusLachnospiraceae bacterium GAM79Image: streptococcus thermophilusPhocaeicola vulgatusImage: streptococcus thermophilusImage: streptococcus thermophilusImage: streptococcus thermophilusBacteroides streptosiImage: streptococcus thermophilusImage: streptococcus thermophilusImage: streptococcus thermophilusIm	Mitsuokella jalaludinii	0.0242	0.0103	0.0305	0.0390	
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusImage: streptococcus faecium prausnitziiImage: streptococcus faecium faeciumImage: streptococcus faecium faeciumImage: streptococcus faecium faeciumImage: streptococcus faecium faeciumImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus streptopilusImage: streptopilusImage: streptopilusImage: streptopilusImage: streptococcus streptopilusImage: s	Bacteroides stercoris				0.0236	
Phascolarctobacterium succinatutensImage: section of the	Phocaeicola vulgatus		0.0254		0.0332	
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusStreptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusEubacterium siraeumImage: streptococcus facciumImage: streptococcus facciumFaecalibacterium prausnitziiImage: streptococcus facciumImage: streptococcus facciumPhascolarctobacterium faeciumImage: streptococcus facciumImage: streptococcus facciumPhascolarctobacterium faeciumImage: streptococcus facciumImage: streptococcus facciumBacteroidales bacterium CFImage: streptococcus faeciumImage: streptococcus faeciumRuminococcus gnavusImage: streptococcus thermophilusImage: streptococcus faeciumStreptococcus thermophilusImage: streptococcus thermophilusImage: streptococcus thermophilusBacteroides faecisImage: streptococcus thermophilusImage: streptococcus thermophilusChristensenella minutaImage: streptococcus thermophilusImage: streptococcus thermophilusLachnospiraceae bacterium GAM79Image: streptococcus thermophilusImage: streptococcus thermophilusLachnospiraceae bacterium GAM79<	Christensenella massiliensis	0.0320				
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusImage: streptococcus sali	Lachnospiraceae bacterium GAM79	0.0485				
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusFaecalibacterium prausnitziiImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumPhascolarctobacterium faeciumImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumPhascolarctobacterium faeciumImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumBacteroidales bacterium CFImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumRuminococcus gnavusImage: streptococcus thermophilusImage: streptococcus faeciumImage: streptococcus faeciumStreptococcus thermophilusImage: streptococcus thermophilusImage: streptococcus faeciumImage: streptococcus faeciumGhristensenella minutaImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumGhristensenella minutaImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus thermophilusImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus thermophilusImage: streptococcus faecium	Escherichia coli					
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusStreptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusFaecalibacterium siraeumImage: streptococcus faeciumImage: streptococcus faeciumFhascolarctobacterium faeciumImage: streptococcus faeciumImage: streptococcus faeciumPhascolarctobacterium faeciumImage: streptococcus faeciumImage: streptococcus faeciumClostridium saccharogumiaImage: streptococcus gnavusImage: streptococcus thermophilusRuminococcus gnavusImage: streptococcus thermophilusImage: streptococcus thermophilusBacteroides faecisImage: streptococcus thermophilusImage: streptococcus thermophilusBacteroides faecisImage: streptococcus thermophilusImage: streptococcus thermophilusChristensenella minuta0.0057Image: streptococcus thermophilus	Anaeromassilibacillus senegalensis	0.0150				-0
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusFaecalibacterium prausnitziiImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumPhascolarctobacterium faeciumImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumClostridium saccharogumiaImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumBacteroidales bacterium CFImage: streptococcus faeciumImage: streptococcus faeciumImage: streptococcus faeciumRuminococcus gnavusImage: streptococcus thermophilusImage: streptococcus thermophilusImage: streptococcus thermophilusBacteroides faecisImage: streptococcus t	Christensenella minuta	0.0057				0.0
Phascolarctobacterium succinatutensImage: section of the	Bacteroides faecis					0.0
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusStreptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusEubacterium siraeumImage: streptococcus facuimImage: streptococcus facuimFaecalibacterium prausnitziiImage: streptococcus facuimImage: streptococcus facuimKlebsiella pneumoniaeImage: streptococcus facuimImage: streptococcus facuimPhascolarctobacterium faeciumImage: streptococcus facuimImage: streptococcus facuimClostridium saccharogumiaImage: streptococcus facuimImage: streptococcus facuimBacteroidales bacterium CFImage: streptococcus facuimImage: streptococcus facuimSuccinivibrio dextrinosolvensImage: streptococcus facuimImage: streptococcus facuimRuminococcus gnavusImage: streptococcus facuimImage: streptococcus facuimRuminococcus torquesImage: streptococcus facuimImage: streptococcus facuim	Streptococcus thermophilus					0.2
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusStreptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusFaecalibacterium siraeumImage: streptococcus faeciumImage: streptococcus faeciumFaecalibacterium prausnitziiImage: streptococcus faeciumImage: streptococcus faeciumPhascolarctobacterium faeciumImage: streptococcus faeciumImage: streptococcus faeciumPhascolarctobacterium faeciumImage: streptococcus faeciumImage: streptococcus faeciumBacteroidales bacterium CFImage: streptococcus faeciumImage: streptococcus faeciumSuccinivibrio dextrinosolvensImage: streptococcus faeciumImage: streptococcus faeciumRuminococcus gnavusImage: streptococcus faeciumImage: streptococcus faecium	Ruminococcus torques					
Phascolarctobacterium succinatutensImage: streptococcus sp. LPB0220Image: streptococcus salivariusStreptococcus salivariusImage: streptococcus salivariusImage: streptococcus salivariusBacteroides thetaiotaomicronImage: streptococcus salivariusImage: streptococcus salivariusEubacterium siraeumImage: streptococcus faccusImage: streptococcus salivariusFaecalibacterium prausnitziiImage: streptococcus faccusImage: streptococcus faccusKlebsiella pneumoniaeImage: streptococcus faccusImage: streptococcus faccusPhascolarctobacterium faeciumImage: streptococcus faccusImage: streptococcus faccusClostridium saccharogumiaImage: streptococcusImage: streptococcusBacteroidales bacterium CFImage: streptococcusImage: streptococcusSuccinivibrio dextrinosolvensImage: streptococcusImage: streptococcus	Ruminococcus gnavus					
Phascolarctobacterium succinatutensImage: sector of the secto	Succinivibrio dextrinosolvens					
Phascolarctobacterium succinatutensImage: sector of the secto	Bacteroidales bacterium CF					
Phascolarctobacterium succinatutensImage: sector of the secto	Clostridium saccharogumia					
Phascolarctobacterium succinatutensImage: Constraint of the sector of the s	Phascolarctobacterium faecium					
Phascolarctobacterium succinatutensImage: Streptococcus sp. LPB0220Image: Streptococcus salivariusStreptococcus salivariusImage: Streptococcus salivariusImage: Streptococcus salivariusBacteroides thetaiotaomicronImage: Streptococcus salivariusImage: Streptococcus salivariusEubacterium siraeumImage: Streptococcus salivariusImage: Streptococcus salivariusFaecalibacterium prausnitziiImage: Streptococcus salivariusImage: Streptococcus salivariusKlebsiella pneumoniaeImage: Streptococcus salivariusImage: Streptococcus salivarius	Enterococcus faecium					
Phascolarctobacterium succinatutens Image: Construction of the second secon	Klebsiella pneumoniae					
Phascolarctobacterium succinatutens Image: Construction of the second secon	Faecalibacterium prausnitzii					
Phascolarctobacterium succinatutens Image: Construction of the second secon	Eubacterium siraeum					
Phascolarctobacterium succinatutens	Bacteroides thetaiotaomicron					
Phascolarctobacterium succinatutens	Streptococcus sp. LF B0220					
	Phascolarciobacterium succinatulens					-
Enterocioster bolteae						

<u>;9</u>

50 51

52

53

54

55

56 57

58

59

70

71

12

13

14

15

Fig. 6. Heatmap of correlations between gut microbiota species, somatic and **neuropsychiatric symptoms.** Heatmap illustrating the Spearman's correlation coefficients between the centered log-ratio (CLR) transformed abundances of gut microbial species and scores from four assessments: PHQ-15 (somatic symptoms), PSS (perceived stress), HADS-A (anxiety), and HADS-D (depression). The color scale represents the strength and direction of correlations, with red indicating positive correlations and blue indicating negative correlations. The intensity of the color corresponds to the magnitude of the correlation, as shown in the legend on the right (ranging from -0.25 to 0.25). P-values are less than 0.05displayed on corresponding cells, indicating statistical significance. Blank cells represent correlations that did not meet the significance threshold. Bacterial species are listed on the y-axis, while the mental health scales are shown on the x-axis. This visualization allows for identifying specific microbial species that may have consistent or unique associations with different aspects of mental health as measured by these indicators. Notable correlations include positive associations between Mitsuokella jalaludinii and all measurements, and negative associations between several species (e.g., Christensenella massiliensis, Lachnospiraceae bacterium GAM79) and PHQ-15 scores.

76

Multivariate analysis and network visualization of gut microbial associations with somatic and neuropsychiatric symptoms in COVID-19 patients.

17

78

79

30

31

32

33

34

35

36

37

38

39

)()

)1

To further explore the relationship among somatic and neuropsychiatric symptoms, COVID-19 severity, and gut microbiome composition, a redundancy analysis (RDA) was conducted. This analysis visualized the distribution of microbial species with COVID-19 severity (low, moderate, critical) and all assessments (PHQ-15, PSS, HADS-A, HADS-D). The RDA plot (**Fig. 7a**) shows the relationship between gut microbial species and PHQ-15, PSS, HADS-A, and HADS-D scores across different COVID-19 severity groups. The RDA axes account for 4.9% and 1.4% of the variation, respectively. Notably, the species *Mitsuokella jalaludinii* was positioned within the mental health indicator constraints of the plot, suggesting potential associations with specific assessed symptoms or COVID-19 severity outcomes. Distinct relationships were observed, with species such as *Phocaeicola vulgatus*, *Bacteroides stercoris*, and *Prevotella copri* being positively associated with elevated somatic scores, particularly in patients with critical disease.



Fig. 7. Associations between gut microbiota, somatic and neuropsychiatric symptoms)2 in hospitalized COVID-19 patients. (a) Redundancy Analysis (RDA) plot showing the)3 association between gut microbiome composition, somatic and neuropsychiatric symptoms,)4 and COVID-19 severity. The x-axis represents RDA1 (4.9% of variation), and the y-axis)5 represents RDA2 (1.4%). Each point represents an individual patient, color-coded by)6 COVID-19 severity. Green arrows indicate the direction and strength of association with)7 PHO-15, PSS, HADS-A, and HADS-D. Labeled bacterial species show their associations)8 with these factors. Density plots on the top and right margins show the distribution of)9 samples along each axis. (b) Venn diagram of the resulting driver taxa from each COVID-)0 19 severity group using the BakDrive interaction analysis followed by the BakDrive driver)1 analysis. Genera that are bolded correspond to taxa that are above the total relative)2

It is made available under a CC-BY-NC-ND 4.0 International license .

abundance threshold of 5%. (c) SpiecEasi, sparse and low-rank decomposition network)3)4 analysis of gut microbiome species, illustrates the co-occurrence patterns of gut bacterial species associated with mental health indicators. Nodes represent bacterial species with a)5 p<0.05 with any mental health index, while edges represent significant correlations between)6 species. Node colors represent Spearman's correlation between the microbe and the scores)7 of the assessments. Together, these visualizations provide insights into the complex)8 relationships between gut microbiome composition, mental health status, and COVID-19)9 severity, suggesting potential microbial signatures associated with different symptoms in 0 the context of COVID-19 infection. 1

Conversely, species Christensenella minuta, Anaeromassilibacillus senegalensis, and 2 Lachnospiraceae bacterium GAM79 negatively correlated with somatic symptoms, 3 suggesting a potential protective effect. To investigate which microbial taxa might drive the 4 severity of COVID-19 in gut microbiomes, we used Bakdrive(25). Bakdrive is a microbial 5 community modeling tool designed to identify driver bacteria that play a pivotal role in 6 influencing the structure and function of the microbiome in health or disease. Specifically, .7 by utilizing metabolic models and network analysis, Bakdrive aims to pinpoint taxa that 8 play crucial roles in disease mechanisms or ecological interactions. Using this tool, we can 9 20 highlight the bacterial species that were likely driving interactions within gut microbiomes across low, moderate, and critical severity groups. Specific taxa exhibited varying 21 prevalence across different levels of COVID-19 severity (Supplementary Table 3). For 22 example, Granulicatella was predominantly present in critically ill patients, while 23 Succinivibrio was more common among those with moderate disease severity. Some driver 24 taxa were shared between severity groups. Notably, Faecalibacterium was present across 25 all severity levels, and *Enterococcus* appeared only in patients with low and moderate 26 severity. These findings reflect distinct variations in driver taxa composition associated with 27 disease severity scores (Fig. 7b). 28

The network diagram generated using SpiecEasi (Sparse InversE Covariance estimation for 29 Ecological Association Inference) illustrated the associations between specific microbial 30 species and various symptoms assessed, highlighting Spearman correlations with p-values 31 <0.05 related to mental health indicators (Fig. 7c). This network highlights the intricate 32 interactions among bacterial species, with nodes color-coded to reflect their associations 33 with PHO-15, PSS, HADS-A, and HADS-D scores. The structure reveals positive and 34 negative associations between species, computed using the sparse and low-rank 35 decomposition method. This approach minimizes the impact of latent variables, allowing 36 for a more precise representation of the complex balance within the gut microbiome with 37 mental health and COVID-19 severity. Microbial species such as Mitsuokella jalaludinii 38 and Phocaeicola vulgatus strongly correlated with PSS and HADS-D. Conversely, species 39 Christensenella minuta, Anaeromassilibacillus senegalensis, and Lachnospiraceae 10 bacterium GAM79 were inversely associated with PHQ-15. Key species Ruminococcus 11 *lactaris, Megasphaera indica, and Bacteroides stercoris* occupy central positions within the 12 network, indicating their potential significance in the gut-brain axis and their possible role 13 in influencing mental health status. 14

It is made available under a CC-BY-NC-ND 4.0 International license .

15 **Discussion**

This proof-of-concept study highlights links between somatic and neuropsychiatric symptoms, inflammatory responses, and gut microbiome dysbiosis in hospitalized COVIDpatients. The results provide essential insights into the intricate interactions between COVID-19 severity and specific microbial species, demonstrating that different microbes are associated with varying levels of disease severity and neuropsychiatric co-morbidities.

In this study, most patients experienced at least three COVID-19 symptoms, with dyspnea 51 significantly associated with increased disease severity. Consistent with previous research, 52 older age, and male gender were linked to more severe manifestations of COVID-19, 53 reaffirming age as a significant risk factor for severe outcomes(4, 5). Somatic symptoms, 54 stress, anxiety, and depressive symptoms were common across all severity levels. This 55 aligns with other studies reporting a high prevalence of physical symptoms and mental 56 health issues among hospitalized COVID-19 patients during the same period(10, 11, 26, 57 27). Notably, a higher proportion of women reported anxiety and had higher scores on the 58 HADS-A scale compared to men. Individuals with higher stress levels also experienced 59 more extended hospital stays. These findings are consistent with studies identifying women 50 as a vulnerable group for mental health issues, including perceived stress(26) and 51 anxiety(27). 52

Our results align with existing literature regarding alterations in blood cells and markers 53 among critically ill patients, such as reduced lymphocytes, elevated neutrophils, increased 54 55 CRP, D-dimer, and ferritin levels, and comorbidities like hypertension and heart diseases (28). These findings underscore the significant role of systemic inflammation and pro-56 thrombotic responses in exacerbating COVID-19 severity(29-31). SARS-CoV-2 infection 57 triggers immunopathological reactions characterized by intense cytokine production, known 58 as the cytokine storm(32). Elevated levels of IL-6, as observed in our study, are frequently 59 reported, especially in individuals over 60 years old with comorbidities, and are recognized 70 71 as markers of disease severity storm(32). Elevated IL-6 is associated with increased production of acute-phase proteins like CRP and other inflammatory cytokines(29-31). In 12 line with other findings, IL-1ra, IL-10, and IFN- γ were significantly elevated in patients 13 with severe COVID-19(30). The increase in IL-10 and IL-1ra may reflect a compensatory 14 anti-inflammatory response to elevated pro-inflammatory cytokines, attempting to mitigate 15 the harmful effects of the cytokine storm(33). However, this response appears ineffective, 16 17 as elevated IL-10 levels are associated with poor clinical outcomes and reduced survival rates(33, 34). Additionally, we observed decreased levels of IL-2 in critically ill patients, 78 79 which may represent a response aimed at preventing viral spread during the early phase of the disease (35). 30

An inverse relationship was observed between disease severity and the abundance of 31 beneficial bacteria. Alpha diversity and species richness were significantly reduced in 32 critically ill patients, reinforcing previous findings of microbiome dysbiosis in severe 33 COVID-19 cases(36). This diversity reduction aligns with findings linking diminished gut 34 microbial diversity to poor symptoms and heightened inflammatory responses(37). 35 Consistent with this, beta diversity analyses revealed distinct microbial profiles influenced 36 by factors such as BMI, gender, and age, as reported by other studies (38), highlighting the 37 impact of these demographic factors on the gut microbiome during COVID-19 infection. 38 Severely ill patients exhibited a decline in beneficial bacterial taxa, including 39 Christensenella minuta and Lachnospiraceae, which are known to support gut health, and)() their reduction suggests a weakening of the intestine's protective functions. This could lead)1)2 to dysbiosis, a decrease in short-chain fatty acids (SCFA), crucial for maintaining intestinal

It is made available under a CC-BY-NC-ND 4.0 International license .

- integrity and regulating immune responses, ultimately contributing to poorer mental health)3)4 outcomes in severely ill patients. Another study during the same period found that severely symptomatic SARS-CoV-2 patients had significantly lower bacterial diversity and reduced)5 abundances of beneficial bacteria, such as Bifidobacterium, Faecalibacterium, and)6 Roseburium while showing an increase in *Bacteroides* compared to controls(39). Several)7 bacterial taxa associated with SARS-CoV-2 infection were identified, notably elevated)8 levels of Granulicatella and Rothia mucilaginosa found in both the oral and gut)9 microbiomes(40). Consistent with our findings, Granulicatella was exclusively)0 predominant in critical patients.)1
- An increase in opportunistic pathogens, like *Klebsiella pneumoniae* and *Parabacteroides*)2 distasonis, can intensify inflammation, raise infection risks, and potentially worsen a)3 patient's overall health (41). For instance, Klebsiella pneumoniae was commonly associated)4 with critically ill patients and linked to severe conditions like pneumonia and sepsis(41).)5 Certain pathogens have also been associated with specific symptoms in long-term COVID-)6 19; for example, *Clostridium innocuum* has been suggested to play a role in neuropsychiatric)7 symptoms(42). Many gut microbiome taxa associated with known comorbidities, such as)8 Veillonella dispar, Veillonella parvula, and Streptococcus gordonii, are typically found)9 within the oral cavity. Their presence in the gut aligns with several other studies showing a 0 link between disease severity and oral taxa within the gut microbiome(43). Bacterial genera 1 such as Eubacterium, Agathobacter, Subdoligranulum, Ruminococcus, and Veillonella 2 show notable shifts in abundance. 3
- Interestingly, we observed that specific microbial species were associated with somatic 4 5 symptoms, perceived stress, anxiety, and depressive symptoms, offering insights into the complex microbial dynamics, the gut-brain axis, and mental health indicators in COVID-.6 19. The gut microbiome influences neuropsychiatric symptoms through microbial 7 metabolites like SCFA, which regulate immune cells and neurotransmitter production, and 8 through the gut-brain axis(44). Imbalances in gut microbes can lead to increased 9 inflammation and disrupted communication, contributing to conditions like anxiety, 20 depressive symptoms, and cognitive decline (44, 45). Furthermore, the gut microbiome has 21 been suggested to be a key modulator of psychological health during and after COVID-19 22 23 infection (37, 45).
- Differential abundance analyses showed that several microbial species were significantly 24 associated with psychological measures, including somatic symptoms, perceived stress, 25 anxiety, and depressive symptoms. The clustering of species like *Phocaeicola vulgatus*, 26 Bacteroides stercoris, Ruminococcus lactaris, Megasphaera indica, and Mitsuokella 27 *jalaludinii* around elevated somatic or neuropsychiatric scores suggests that these microbes 28 may play a vital role in the gut-brain axis during COVID-19. Mitsuokella jalaludinii was 29 positively correlated with all assessments, suggesting its role in worsening mental 30 31 health (46). In contrast, species like Christensenella minuta and Anaeromassilibacillus senegalensis were negatively associated with PHQ-15. These findings align with growing 32 evidence that links gut dysbiosis to mood disorders and stress-related conditions. 33
- Limitations of this study include its cross-sectional design, which prevents establishing causality between gut microbiome alterations and neuropsychiatric symptoms. Potential confounding factors such as pre-existing mental health conditions or medication use were not controlled for, and a lack of a healthy control group limits the ability to compare findings to non-COVID-19 individuals. Additionally, a larger sample size may be required to generalize the results to all hospitalized COVID-19 patients. Finally, fecal microbial load may represent a major confounder (*47*).

Recovery from SARS-CoV-2 infection has been linked to greater psychosocial resilience 11 (27), while individuals with higher levels of mental distress during the acute phase are more 12 vulnerable to long-term effects (48). Hospitalized patients who experienced severe COVID-13 19 face a greater risk of developing Long COVID compared to those with mild cases(49). 4 Our meta-analysis, published in 2021, found that 8 out of 10 individuals with SARS-CoV-15 2 infections exhibited symptoms of Long COVID(50). However, recent epidemiological 16 data offer a more conservative estimate, Long COVID risk at three months post-infection is 17 now reported at 6.2%(49, 51). It is very important to consider parameters with strong 18 discriminatory power to stratify patient risk and classify the severity of COVID-19(52). 19 Randomized controlled trials are necessary to assess the effectiveness of microbiome-50 targeted therapies, such as probiotics and dietary interventions. Mechanistic studies should 51 investigate how microbiome changes influence systemic inflammation during the acute 52 phase of COVID-19 and how these interactions may predict the onset and progression of 53 neuropsychiatric symptoms. This research may help guide the development of clinical 54 guidelines and patient monitoring strategies for incorporating microbiome-based 55 interventions into COVID-19 treatment. 56

In conclusion, our study provides data in support of the hypothesis that immune responses 57 and the gut-brain axis may be playing a role in regulating somatic and neuropsychiatric 58 symptoms during acute COVID-19. Probiotics, prebiotics, and dietary modifications, such 59 as increasing fiber or omega-3 intake to restore microbial balance, could reduce the severity 50 of symptoms. Additionally, microbiome-targeted therapies or pharmaceutical approaches 51 that modulate gut health offer promising avenues to improve recovery and mitigate the risk 52 53 of severe complications in COVID-19 patients. Further research is needed to explore whether modulating the gut microbiota could alleviate neurological symptoms during the 54 infection phase and impact the development of Long COVID. 55

58 Materials and Methods

59 70

71

12 13

74 75

16

17

78

56 57

Study Design

This cross-sectional study was based on an exploratory analysis of baseline data from hospitalized COVID-19 patients who participated in a randomized clinical trial investigating the effects of a dietary supplement containing tannins(53). The study protocol has been detailed in a prior report(54). The study was approved by the Ethics Committee of the Hospital de Clínicas José de San Martín (1046-20) in accordance with the guidelines of the Argentine Ministry of Health and the hospital's treatment protocols. The demographics and clinical characteristics of the participants are presented in **Table 1**, and the methodology is outlined in **Fig. 9**. This study was performed between 1 March 2020 and 31 October 2021.

19

It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 9. Overview of data collection and analysis for hospitalized COVID-19 patients.

30 31 32

33

34

35

36

37

38

39

)0

)1

)2

)3

)4

)5

)6

)7

)8

)9

This comprehensive data collection framework aims to provide a holistic understanding of the COVID-19 symptoms and somatic, neuropsychiatric, and microbiological aspects of COVID-19 in hospitalized patients. (a) Clinical and Demographic Data. COVID patients (n=124) are categorized into three severity groups based on a scoring index: low (0-2), moderate (3-7), and critical (>8). This score is based on age, gender, heart failure, chronic obstructive pulmonary disease (COPD), diabetes mellitus, heart rate, respiratory rate, systolic blood pressure, temperature, oxygen saturation, including in patients with COPD, D-dimer levels, lymphocyte and platelet counts, dyspnea, chest X-ray alterations, and the need for supplemental oxygen. (b) Somatic and Neuropsychiatric Assessments: Patient Health Questionnaire-15 (PHQ-15) is used to assess somatic symptoms, including stomach pain, back pain, pain in arms, legs, and joints, menstrual cramps, headaches, chest pain, dizziness, fainting spells, heart palpitations, shortness of breath, pain during sexual intercourse, constipation, nausea, indigestion, fatigue, and trouble sleeping. Additional neuropsychiatric assessments include the Perceived Stress Scale (PSS), Hospital Anxiety and Depression Scale-Anxiety (HADS-A), and Hospital Anxiety and Depression Scale-Depression (HADS-D). (c) Laboratory Tests. Various serological assays are conducted to analyze hematological, coagulation, and biochemical parameters, and serum inflammatory

It is made available under a CC-BY-NC-ND 4.0 International license .

cytokines. (d) Microbiome Analysis. Stool samples are collected for microbiome analysis. Full-length 16S sequencing is performed using Oxford Nanopore Technologies, followed by microbial composition analysis using Emu. Data analysis uses tools such as phyloseq, ANCOMBC2, and SpiecEasi to understand the microbial landscape and its association with disease severity and patient outcomes.

COVID-19 severity classification

)()

)1

)2

)3

)4)5

)6

)7

)8

)9

0

1

2

4

5

6

7

8

9

20

21

22

23

24 25

26

27

28

29

30

31

32

33

34

35 36

37

Using the COVID-19 severity index, patients were classified into low, moderate, or critical disease severity(55). This index incorporates the following multiple variables: age, gender, comorbidities, dyspnea, chest X-ray abnormalities, and the requirement for supplemental oxygen (Fig.9). The X-ray was performed at the time of hospital admission. Here, we considered scores of 0–2 to indicate low severity, 3–7 as moderate, and 8 or higher as critical severity of COVID-19 adapted from Huespe et al. (56) (Supplementary Table 1).

Somatic and neuropsychiatric symptoms

Somatic symptoms were assessed using the Patient Health Questionnaire-15 (PHQ-15), while the perception of stress was evaluated with the Perceived Stress Scale (PSS). Anxiety and depressive symptoms were measured using the Hospital Anxiety and Depression Scale (HADS), with all somatic and neuropsychiatric symptoms being self-reported. Only 77 patients could complete the instruments, which was influenced by the severity of the clinical condition and transfer to the intensive care unit at the time of hospital admission. The PHO-15 consists of 15 items that assess the severity of somatic symptoms over the previous week(57) (Fig. 9). Each symptom is scored as 0 ("not bothered at all"), 1 ("bothered a little"), or 2 ("bothered a lot"). The PHQ-15 score ranges from 0 to 30, (0-28 in men) with cutoff points at >5 for low, >10 for moderate, and >15 for high somatic symptom severity (57). Scores of 15 or higher are indicative of severe somatic symptoms. The PSS(58)is a self-report measure that assesses the perception of stress over the previous month. The version of the PSS used was the 14-item version, which includes seven positive and seven negative items that assess feelings of chaos, lack of control, and overall stress without being tied to specific events. Each item is rated on a 5-point scale from 0 ("never") to 4 ("very often"), with higher scores indicating more significant stress. The categories are rarely or never (less than 14 points); occasionally (14-28 points); often (29-42 points); and usually (42-56 points). The HADS(59) is a self-report rating scale of 14 items designed to measure anxiety and depression (7 items for each subscale). Each item is scored from 0 ("absence") to 3 ("extreme presence"). Each subscale has a total score ranging from 0 to 21, with scores of 0–7 indicating "normal," 8–10 "mild," 11–14 "moderate," and 15–21 "severe" symptoms.

Blood biomarkers

Blood samples were collected by venipuncture within 48 hours of hospital admission and 38 placed in vacutainer tubes with a clot activator. Serum was obtained by centrifugation at 39 $3,000 \times$ g for 15 minutes at 4°C. Circulating cytokine levels were evaluated using the Bio-10 Plex Pro[™] Human Cytokine Standard 27-Plex Kit (Bio-Rad), following the manufacturer's 11 instructions. This assay measures 27 different molecules: IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, 12 IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, IL-1β, IL-1ra, TNF-α, IFN-γ, IP-10, MCP-1, MIP-13 1α, MIP-1β, eotaxin, FGF, G-CSF, GM-CSF, VEGF, and PDGF-BB. Serum levels of the 14 inflammatory mediators were reported as median fluorescence intensity (MFI). Counts of 15

leukocytes, neutrophils, lymphocytes, and platelets were measured. The neutrophil-tolymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were subsequently calculated. Coagulation parameters assessed included prothrombin time, activated partial thromboplastin time (aPTT), D-dimer, and fibrinogen levels. Inflammatory markers, specifically C-reactive protein (CRP) and ferritin were evaluated to analyze inflammatory status. Additionally, biochemical analyses were conducted to determine the concentrations of albumin, creatine kinase (CK), and lactate dehydrogenase (LDH).

Nanopore 16S rRNA library preparation and sequencing

Stool samples were collected using µb-eNAT preservation tubes (COPAN®, Italy), aliquoted, and stored at -80 °C until analysis. DNA was extracted from 100 mg of homogenized fecal samples employing the MagMAXTM Microbiome Ultra Nucleic Acid Isolation Kit, following the manufacturer's protocol. Subsequently, 16S rRNA amplicon libraries were prepared using the 16S Barcoding Kit 1-24 (SQK-16S024) from Oxford Nanopore Technologies (ONT), Oxford, UK. For PCR amplification and barcoding, 18 ng of extracted DNA was combined with LongAmp Hot Start Taq 2X Master Mix (New England Biolabs, Ipswich, MA) according to the manufacturer's instructions. The thermal cycling protocol consisted of an initial denaturation at 95 °C for 20 seconds, followed by 35 cycles of 95 °C for 20 seconds, 55 °C for 30 seconds, and 65 °C for 2 minutes, concluding with a final extension at 65 °C for 5 minutes. The resulting barcoded amplicons were purified using AMPure XP beads (Beckman Coulter, Brea, CA). After purification, the amplicons were quantified with a Qubit fluorometer (Life Technologies, Carlsbad, CA) and pooled in an equimolar ratio to achieve 100 ng in 10 µL. The pooled library was then loaded into an R9.4.1 flow cell and sequenced on the MinION platform (Oxford Nanopore Technologies, Oxford, UK) using MINKNOW software version 19.12.5 for data acquisition.

Bioinformatic Analysis

Full-length 16S sequences were converted to pod5 format and called using Dorado v0.5.0 with the dna r9.4.1 e8 sup@v3.6 model. The resulting BAM files were demultiplexed and converted to fast files using the Dorado demux command(60). Fast files for each sample were then concatenated using SeqKit scat v2.7.0, processed with the Emu taxonomic taxonomic classification software v3.4.5, and aggregated into an Operational Taxonomic Unit (OTU) output table(61). The OTU and taxonomy tables were integrated with metadata to create a phyloseq v1.48.0 object (62). A phylogenetic tree was created using the Emu taxdump to tree.py script to generate a reference tree based on the Emu database. Using a custom Python script (https://github.com/villapollab/covid biome) and a mapping file specific to the dataset, leaves that matched within the reference tree were retained and converted to their corresponding OTU identifiers in the phyloseq object. The phylogenetic tree was merged with the phyloseq object using the ape v5.8 read.tree function, enabling phylogenetic calculations within phyloseq(63). Subsequent analyses included alpha diversity, beta diversity, and abundance and correlation heatmaps, performed using MicroViz v0.12.4(64). Network correlations were obtained using SpiecEasi version 1.1.3(65). All data analyses following Emu classification were executed using Python v3.12 and R v4.3.3(66, 67).

)1

)2

16

17

18

19

50

51

52 53 54

55

56

57 58

59

50

51 52

53

54

55

56

57

58

59

70

71

12

13

14

15

י6 7י

18

79

30

31

32

33

34 35

36

37

38

39

)()

Differential Abundance and Driver Species Analysis

To obtain a comprehensive understanding of potential bacterial driver species within the gut)3)4 microbial communities of COVID-19 patients of differing severity, we employed Bakdrive v1.0.4(25) and ANCOMBC2 v2.6.0(68). Bakdrive is a microbial community modeling tool)5 designed to identify driver bacteria-bacteria that play a pivotal role in influencing the)6 structure and function of the microbiome in health or disease. Specifically, by utilizing)7 metabolic models and network analysis, Bakdrive attempts to pinpoint taxa that may be)8 critical in disease mechanisms or ecological interactions. ANCOMBC2 (Analysis of)9)0 Composition of Microbiomes with Bias Correction 2) is a differential abundance analysis tool designed to address the compositional nature of microbiome data and corrects for)1 biases, enabling accurate identification of taxa that are differentially abundant between)2 sample groups. A detailed notebook of the bioinformatic analysis can be found at)3 https://villapollab.github.io/covid_biome/.)4

Statistical Analysis

Categorical variables were presented as frequencies and percentages. To analyze)7 contingency tables for variables such as gender, mortality, antibiotic use, supplemental)8)9 oxygen, and COVID-19 symptoms, the Chi-square (χ^2) test or Fisher's exact test (FET) was employed. The normality of the distribution of numerical variables was assessed with a 0 Kolmogorov-Smirnov test. Depending on their distribution, numerical variables were 1 presented as median and interquartile range (IQR) or mean and standard deviation (SD). For 2 comparisons between two groups, the Independent Samples t-test was used for normally 3 distributed variables, while the Mann-Whitney U test was applied for non-normally 4 5 distributed variables (e.g., PSS, HADS-A, HADS-D between groups with and without severe somatic symptoms). One-way ANOVA was utilized to examine differences in .6 parametric variables such as age and BMI across COVID-19 severity categories (low, 7 moderate, and critical), followed by Tukey's Honest Significant Difference (HSD) post hoc 8 test. For non-parametric variables, including days of hospitalization, number of COVID-19 9 symptoms, PHO-15, PSS, HADS-A, and HADS-D, the Kruskal-Wallis test was performed. 20 This was followed by pairwise comparisons between severity groups with correction for 21 multiple testing. Linear regression analysis compared cytokine levels with and without 22 adjustment for age, gender, and BMI. Associations between clinical outcomes and 23 inflammatory mediators or gut microbiota were assessed using Spearman's rank correlation 24 coefficients (e.g., correlations between PHQ-15, PSS, HADS-A, and HADS-D). All 25 statistical analyses were performed using IBM SPSS Statistics for Windows, version 25 26 (IBM Corp., Armonk, NY, USA). A p-value of <0.05 was considered statistically 27 significant. 28

29

)5

)6

It is made available under a CC-BY-NC-ND 4.0 International license .

References

32

- A. M. Afsahi *et al.*, Brain MRI findings in neurologically symptomatic COVID-19
 patients: a systematic review and meta-analysis. *J Neurol* 270, 5131-5154 (2023).
- M. J. Hawkings *et al.*, A Systematic Review of the Prevalence of Persistent
 Gastrointestinal Symptoms and Incidence of New Gastrointestinal Illness after Acute
 SARS-CoV-2 Infection. *Viruses* 15, (2023).
- S. Villapol, Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. *Transl Res* 226, 57-69 (2020).
- 4. H. Peckham *et al.*, Male sex identified by global COVID-19 meta-analysis as a risk factor
 for death and ITU admission. *Nat Commun* 11, 6317 (2020).
- D. K. Twitchell *et al.*, Examining Male Predominance of Severe COVID-19 Outcomes: A
 Systematic Review. *Androg Clin Res Ther* 3, 41-53 (2022).
- E. J. Williamson *et al.*, Factors associated with COVID-19-related death using
 OpenSAFELY. *Nature* 584, 430-436 (2020).
- 7. Z. Wu, J. M. McGoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases
 From the Chinese Center for Disease Control and Prevention. *JAMA* 323, 1239-1242
 (2020).
- M. Hosseini Largani *et al.*, Depression, Anxiety, Perceived Stress and Family Support in
 COVID-19 Patients. *Iran J Psychiatry* 17, 257-264 (2022).
- N. Yildirim, H. Dayilar Candan, A. H. Inan, Psychological Distress in Patients with
 COVID-19 During Hospitalization. *Clin Nurs Res* 31, 376-384 (2022).
- A. Zandifar *et al.*, Prevalence and severity of depression, anxiety, stress and perceived
 stress in hospitalized patients with COVID-19. *J Diabetes Metab Disord* 19, 1431-1438
 (2020).
- I. Saidi, P. P. Koumeka, S. Ait Batahar, L. Amro, Factors associated with anxiety and
 depression among patients with Covid-19. *Respir Med* 186, 106512 (2021).
- X. Li, J. Tian, Q. Xu, The Associated Factors of Anxiety and Depressive Symptoms in
 COVID-19 Patients Hospitalized in Wuhan, China. *Psychiatr Q* 92, 879-887 (2021).
- J. W. Kim *et al.*, Associations Between COVID-19 Symptoms and Psychological Distress.
 Front Psychiatry 12, 721532 (2021).
- M. J. A. Silva *et al.*, Hyperinflammatory Response in COVID-19: A Systematic Review.
 Viruses 15, (2023).
- S. Beyerstedt, E. B. Casaro, E. B. Rangel, COVID-19: angiotensin-converting enzyme 2
 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. *Eur J Clin Microbiol Infect Dis* 40, 905-919 (2021).
- 16. E. P. Tsounis, C. Triantos, C. Konstantakis, M. Marangos, S. F. Assimakopoulos,
 Intestinal barrier dysfunction as a key driver of severe COVID-19. *World J Virol* 12, 68 90 (2023).
- ¹¹ 17. W. Xue, M. Honda, T. Hibi, Mechanisms of gastrointestinal barrier dysfunction in
 ¹² COVID-19 patients. *World J Gastroenterol* 29, 2283-2293 (2023).
- 18. R. Karki *et al.*, Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell
 Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock
 Syndromes. *Cell* 184, 149-168 e117 (2021).
- ¹⁶ 19. J. Schluter *et al.*, The gut microbiota is associated with immune cell dynamics in humans.
 ¹⁷ Nature 588, 303-307 (2020).
- X. Cheng *et al.*, Meta-analysis of 16S rRNA microbial data identified alterations of the gut
 microbiota in COVID-19 patients during the acute and recovery phases. *BMC Microbiol* 22, 274 (2022).

It is made available under a CC-BY-NC-ND 4.0 International license .

31	21.	F. Zhang et al., Gut microbiota in COVID-19: key microbial changes, potential
32		mechanisms and clinical applications. <i>Nat Rev Gastroenterol Hepatol</i> 20, 323-337 (2023).
33	22.	Y. Belkaid, T. W. Hand, Role of the microbiota in immunity and inflammation. Cell 157,
34		121-141 (2014).
35	23.	M. Troseid <i>et al.</i> , Gut microbiota composition during hospitalization is associated with 60-
36		day mortality after severe COVID-19. Crit Care 27, 69 (2023).
37	24.	A. Ratsika, J. S. Cruz Pereira, C. M. K. Lynch, G. Clarke, J. F. Cryan, Microbiota-
38		immune-brain interactions: A lifespan perspective. Curr Opin Neuropiol 78, 102652
39		(2023).
20	25	O. Wang, M. Nute, T. J. Treangen, Bakdrive: identifying a minimum set of bacterial
)1	201	species driving interactions across multiple microbial communities <i>Bioinformatics</i> 39
)2		i47-i56 (2023)
)3	26	N Fren V Zararsiz A Medetalibevoglu I Polat Relationship between Psychological
)/	20.	Resilience Perceived Stress Death Anxiety and Progression of Disease in Individuals
)5		with COVID-19 Noro Psikivatr Ars 60 245-251 (2023)
)6	27	V Hu <i>et al</i> Eactors related to mental health of inpatients with COVID-10 in Wuhan
70 71	21.	China Regin Robay Immun 80 587-503 (2020)
19	28	E M Ince O Alkan Bilik H Ince Evaluating Mortality Predictors in COVID 10
20 20	20.	Intensive Care Unit Detionte: Insights into A ge Preseleitenin, Neutrophil to Lymphoeyte
19		Patia Platalat to Lymphosyte Patia and Farritin Lastate Index Diagnostics (Rasal) 14
)U)1		(2024)
)1)2	20	(2024). M. Hadavati Ch. H. S. Ehrahim Saraja, A. Pakhahi, Clinical and immunological
)2	29.	opmorison of COVID 10 disease between critical and non-critical courses: a systematic
)3)4		review and mote analysis. Event Immunol 15, 1241168 (2024)
)4)5	20	P. Oin et al. Identification of Deremeters Derrogentative of Immuno Dysfunction in
15	30.	R. Qill <i>et al.</i> , Identification of Fatalicies Representative of minimum Dysfunction in Patients with Severe and Fatal COVID 10 Infection: a Systematic Review and Meta
)0)7		analysis Clin Pay Allower Immunol 64, 22, 65 (2022)
)/ \Q	21	I Wong M Jiang V Chan J. J. Montener Cytaking storm and laukagyte changes in
78 10	51.	J. Wang, M. Jiang, A. Chen, L. J. Montaner, Cytokine storm and reukocyte changes in mild various severe SARS CoV 2 infection. Deview of 2020 COVID 10 notions in China
19		and amerging pathogenesis and therepy concerts. <i>LL gulas Piel</i> 109 , 17, 41 (2020)
10	22	M. A. E. Owinse et al. Outabing Profiles Associated With A suite COVID 10 and Lang
1	32.	M. A. F. Queiroz <i>et al.</i> , Cytokine Profiles Associated with Acute COVID-19 and Long
2	22	W Udemainmagert L littikeen S. Senere en americani L. Cheildedkeers, Circulating
.3	<i>33</i> .	W. Odomsinpraseri, J. Jilikoon, S. Sangroongruangsri, U. Chaikiedkaew, Circulating
.4		Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as
.5		Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with
.6	24	Meta-analysis. $J Clin Immunol 41, 11-22 (2021).$
17	34.	M. B. Azaiz <i>et al.</i> , Deciphering the balance of IL-6/IL-10 cytokines in severe to critical
.8	25	COVID-19 patients. Immunobiology 221, 152236 (2022).
.9	35.	L. H. Tjan <i>et al.</i> , Early Differences in Cytokine Production by Severity of Coronavirus
20	2.6	Disease 2019. J Infect Dis 223, 1145-1149 (2021).
21	36.	T. Zuo <i>et al.</i> , Alterations in Gut Microbiota of Patients With COVID-19 During Time of
22		Hospitalization. Gastroenterology 159, 944-955 e948 (2020).
23	37.	O. Manor <i>et al.</i> , Health and disease markers correlate with gut microbiome composition
24		across thousands of people. <i>Nat Commun</i> 11 , 5206 (2020).
25	38.	G. Falony et al., Population-level analysis of gut microbiome variation. Science 352, 560-
26		564 (2016).
27	39.	S. Hazan et al., Lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion
28		and decreased microbiome diversity associated with SARS-CoV-2 infection severity. BMJ
29		Open Gastroenterol 9, (2022).

30 81	40.	Y. Wu <i>et al.</i> , Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization <i>NPL Biofilms Microbiomes</i> 7, 61
)1 12		(2021)
)Z	<i>4</i> 1	(2021). M. K. Paazasa, I. Maasas, Klabsialla nnoumaniaa: Gaing on the Offense with a Strong
)))/	41.	M. K. Faczosa, J. Micesas, Kiedsiena pheumoniae. Comg on the Oriense with a Strong
)4)5	12	O Liu et al. Cut microbiota dynamics in a prospective schort of patients with post south
16	42.	Q. Liu <i>et al.</i> , Out incrobiola dynamics in a prospective conort of patients with post-active COVID 19 syndrome. <i>Gut</i> 71 , 544, 552 (2022)
>0 >7	12	C. Line at al. Oral hastoria relative abundance in faces increases due to aut microbiote
)/ !Q	43.	depletion and is linked with patient outcomes. Nat Microbiol 0 , 1555, 1565 (2024)
)0	11	H Illah <i>et al.</i> The gut microbiote brein evis in neurological disorder. <i>Event Neurosci</i> 17
10	44.	11. Onall <i>et ul.</i> , The gut hild block-blain axis in heurological disorder. <i>From Weurosci</i> 17 , 1225875 (2023)
11	15	M I Butler at al. The aut microbiome in social anxiety disorder: evidence of altered
12	чу.	composition and function Transl Psychiatry 13, 95 (2023)
13	46	I Meng <i>et al</i> Multi-omics analysis reveals the key factors involved in the severity of the
r5 14	т0.	Alzheimer's disease Alzheimers Res Ther 16 213 (2024)
15	47	S Nishijima <i>et al.</i> Fecal microbial load is a major determinant of gut microbiome
۲ <i>3</i> ۱6	ч/.	variation and a confounder for disease associations <i>Cell</i> (2024)
17	48	O Huang <i>et al</i> One-Vear Temporal Changes in Long COVID Prevalence and
18	10.	Characteristics: A Systematic Review and Meta-Analysis Value Health 26 934-947
19		(2023)
50	49	C. C. Global Burden of Disease Long <i>et al</i> Estimated Global Proportions of Individuals
51	12.	With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following
52		Symptomatic COVID-19 in 2020 and 2021. <i>JAMA</i> 328 , 1604-1615 (2022).
53	50.	S. Lopez-Leon <i>et al.</i> , More than 50 long-term effects of COVID-19: a systematic review
54		and meta-analysis. <i>Sci Rep</i> 11 , 16144 (2021).
55	51.	Z. Al-Alv <i>et al.</i> , Long COVID science, research and policy. <i>Nat Med</i> 30 , 2148-2164
56		(2024).
57	52.	I. Huespe <i>et al.</i> , COVID-19 Severity Index: A predictive score for hospitalized patients.
58		Med Intensiva (Engl Ed) 46, 98-101 (2022).
59	53.	S. Molino et al., Randomized placebo-controlled trial of oral tannin supplementation on
50		COVID-19 symptoms, gut dysbiosis and cytokine response. J Funct Foods 99, 105356
51		(2022).
52	54.	S. Molino et al., Natural tannin extracts supplementation for COVID-19 patients
53		(TanCOVID): a structured summary of a study protocol for a randomized controlled trial.
54		<i>Trials</i> 22 , 310 (2021).
55	55.	I. Huespe et al., COVID-19 Severity Index: A predictive score for hospitalized patients.
56		Med Intensiva (Engl Ed) 46, 98-101 (2020).
57	56.	I. A. Huespe et al., Multicenter validation of Early Warning Scores for detection of
58		clinical deterioration in COVID-19 hospitalized patients. Med Intensiva 47, 9-15 (2023).
59	57.	K. Kroenke, R. L. Spitzer, J. B. Williams, The PHQ-15: validity of a new measure for
70		evaluating the severity of somatic symptoms. Psychosom Med 64, 258-266 (2002).
71	58.	S. Cohen, T. Kamarck, R. Mermelstein, A global measure of perceived stress. J Health
'2		<i>Soc Behav</i> 24 , 385-396 (1983).
73	59.	A. S. Zigmond, R. P. Snaith, The hospital anxiety and depression scale. Acta Psychiatr
74		<i>Scand</i> 67 , 361-370 (1983).
15	60.	O. N. PLC., Dorado [https://github.com/nanoporetech/dorado]. Github, (2024).
76	61.	K. D. Curry et al., Microbial Community Profiling Protocol with Full-length 16S rRNA
17		Sequences and Emu. Curr Protoc 4, e978 (2024).
78	62.	P. J. McMurdie, S. Holmes, phyloseq: an R package for reproducible interactive analysis
79		and graphics of microbiome census data. PLoS One 8, e61217 (2013).

- 63. E. Paradis, K. Schliep, ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R. *Bioinformatics* **35**, 526-528 (2019).
- Barnett, Arts, I. & Penders, J., microViz: an R package for microbiome data
 visualization and statistics. *Journal of Open Source Software* 6(63), 3201, (2021).
- Kurtz *et al.*, Sparse and compositionally robust inference of microbial ecological
 networks. *PLoS Comput Biol* 11, e1004226 (2015).
- ³⁶ 66. P. S. Foundation, Python 3.12. Python.org. (2024).
- T. CoreR, R: A Language and Environment for Statistical Computing. *R Foundation for Statistical Computing, Vienna, Austria.*
- ³⁹, (2024).
- H. Lin, S. D. Peddada, Multigroup analysis of compositions of microbiomes with
 covariate adjustments and repeated measures. *Nat Methods* 21, 83-91 (2024).
-)2

)3)4

Acknowledgments

The authors would like to thank Silvia Molino, Andrea Pisarevsky, Fabiana López)6 Mingorance, Patricia Vega, Julieta Repetti, Guillermina Ludueña, Pablo Pepa, and Tatiana)7 Uehara for their collaboration in the data and sample collection at the Hospital de Clínicas)8 José de San Martín, Buenos Aires, Argentina. This work also received funding from)9 Indunor/Silvateam SA. PS is supported by a fellowship from the Coordenação de)() Aperfeiçoamento de Pessoal de Nível Superior, Brazil (CAPES, Finance Code 001). A.M.)1 is supported by a training fellowship from the Gulf Coast Consortia on the NLM Training)2 Program in Biomedical Informatics & Data Science (T15LM007093). The Houston)3 Methodist NeuralCODR Fellowship program supports SS. Fig. 9a was created using)4 BioRender.)5

)6)7

)8

)9

10

8

20

Funding: This work was supported by the National Institute on Aging (National Institutes of Health, NIH) under Award Number R56AG080920 (S.V.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

- Author contributions: SV, PS, AM, SS, KC, TJT, MMP, and SV prepared the manuscript. SV
 supervised the study. MD, TH, and EMQ commented critically on the manuscript and data
 interpretation. MMP contributed to participant recruitment and sample collection. AM, SS,
 KC, and TJT contributed to the computational analysis of the de-identified microbiome
 sequencing data. PS and SV contributed to the study design, data interpretation, analysis,
 and manuscript writing. All authors gave final approval for the version to be published.
- 9 **Competing interests:** Authors declare that they have no competing interests.

Data and materials availability: All data are available in the main text or the
 supplementary materials. The raw sequences generated in this study have been deposited in
 the NCBI Sequence Read Archive (SRA) database under accession PRJNA1179392. All
 bioinformatic data are available on Github:

25 <u>https://github.com/villapollab/covid_biome/releases/tag/medrxiv_sub.</u>